Nova Biomedical Announces Next Generation BioProfile® FLEX 2 Comprehensive Cell Culture Analyzer
FOR IMMEDIATE RELEASE: May 13, 2016
Contact: Matthew McRae
781) 647-3700 ext. 446
Nova Biomedical Announces Next Generation BioProfile® FLEX 2
Comprehensive Cell Culture Analyzer
Waltham, MA – Nova Biomedical announces BioProfile FLEX 2, the next addition to the BioProfile line of cell culture chemistry analyzers. BioProfile FLEX 2 incorporates Nova’s maintenance-free MicroSensor™ Card technology that eliminates sensor maintenance and maximizes workflow efficiency. BioProfile FLEX 2’s very small sample volume allows for automated cell culture analysis for small volume culture systems, such as the Sartorius Ambr® microbioreactor systems.
BioProfile FLEX 2’s innovative design provides comprehensive analysis of 16 key cell culture chemistries including Gluc, Lac, Gln, Glu, NH4+, Na+, K+, Ca++, pH, pCO2, pO2, Osmolality by freezing point depression, and Total and Viable Cell Density and Viability by trypan blue dye exclusion method. The full panel of tests can be run in under four minutes with just 265 microliters of sample, and users can select from manual sampling or two modes for batch sampling: 96-well plates or the built-in 24-position tray.
BioProfile FLEX 2’s maintenance-free technology comprises two credit card-sized MicroSensor cards, each with a minimum 14-day use life and capacity for greater than 500 samples. FLEX 2 reagent cartridges and MicroSensor cards incorporate RFID technology for simple, snap-in replacement with no additional user input. BioProfile FLEX 2’s reagent cartridges combined with maintenance-free MicroSensor Card technology reduce maintenance to just minutes per week.
“We at Nova Biomedical are extremely excited to launch the next addition to the BioProfile line of cell culture analyzers with BioProfile FLEX 2. FLEX 2 represents the most comprehensive platform for cell culture analysis and is also the most robust and easy-to-use system available today,” said Matthew McRae, Biotechnology Sales Product Line Manager at Nova. “We take pride in customer focused designs that provide our end users with the most flexible platform and best workflow of any analyzer in the industry.”
Based on customer input and market need, Nova Biomedical created the small volume BioProfile FLEX 2 to offer the most user-friendly, maintenance-free system that maintains the flexibility and modularity of the first generation BioProfile FLEX analyzer. BioProfile FLEX 2 will help to meet the sizable need for automated cell culture analysis for small volume culture systems like the Sartorius Ambr microbioreactor systems. No other cell culture analyzer provides a complete cell culture test menu and modular and low maintenance design while providing automated sampling from microbioreactor cultures.
Designed for small volume, early stage cell culture development through GMP manufacturing, BioProfile FLEX 2 provides 21CFR Part 11 compliance, OPC connectivity, full networking functionality, and support with all validation needs.
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of state-of-the-art, whole blood, point-of-care and critical care analyzers, as well as providing the biotechnology industry with the most advanced instruments for cell culture monitoring. Nova is one of the fastest growing in vitro diagnostic companies in the world. Nova’s biosensor technology is incorporated in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova’s biotechnology-specific BioProfile line has pioneered comprehensive cell culture testing, providing over 16 critical cell culture tests with 12 unique instrument offerings for broad range of cell culture applications. Nova employs over 1,200 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, France, Germany, Great Britain, Italy, Japan, Spain, Switzerland, and Taiwan.